Business
New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate // Motley Fool Australia
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.
In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.
That rate, meanwhile, is higher than the 90%-plus demonstrated in the…
-
Noosa News11 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
Business22 hours agoWhat I’d buy before the ASX rebounds: 3 high-conviction share picks
-
Noosa News20 hours agoMan shot in the leg during attempted break-in at Beenleigh, Queensland
-
General12 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle